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FINAL EXAMINATION DURATION 
PHA411 – Therapeutics C 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
 
The examination has THREE (A, B and C) Sections: 
Section A: Multiple Choice Questions: Answer ALL (40) questions on the SELS 100-MCQ Answer 
Sheet provided.  Total marks allocated: Twenty (20).  Suggested allocated time: 60 minutes 
Section B:  Extended Answer Questions:  Answer any 4 out of 6 questions.  Marks as indicated by 
lecturer.  Total marks allocated: Forty (40).  Suggested allocated time:  60 minutes. 
Section C:  Case Study Questions:  Answer ALL (2) questions.  Total marks allocated: Forty (40).  
Suggested allocated time:  60 minutes 
EXAM CONDITIONS 
 
You may begin writing from the commencement of the examination session.  The reading time 
indicated above is provided as a guide only. 
This is a CLOSED BOOK examination 
Any non-programmable calculator is permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 
No additional printed material is permitted 
 
1 x 8 Page Book 
1 x 20 Page Book 
1 x 5-Multiple Choice Answer Sheet 
1 x Scrap Paper 
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Section B 
Extended Answer Questions 
Total No of Marks for this section:  40 
 
This section should be answered in the Answer Booklet provided. 
Answer any FOUR (4) questions only. 
 






a) What is meant by ‘carcinoma in situ’ (CIS)?  What are the differences between a CIS 
and a carcinoma? 
 
 (Marks: 5) 
 
b) In the TNM staging system, CIS is reported as TisN0M0 (Stage 0).  Define the TNM 
staging system and discuss how it is used clinically, and its limitations. 
 






a) Discuss the pathophysiology and clinical presentation of benign prostatic hyperplasia 




b) Describe the mechanisms of action of TWO (2) different classes of therapeutic agents 







a) What is “Tumour Lysis Syndrome”?  Outline the signs and symptoms and appropriate 
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a) In relation to palliative care, discuss FIVE (5) symptoms or conditions commonly 
experienced by patients.  Include in your answer an explanation of how these symptoms 
could be managed. 
 
  (Marks: 5) 
 
b) Discuss the role of the pharmacist in palliative care, providing at least 5 reasons why 








a) What is endometriosis?  Include in your answer at least TWO (2) symptoms, how it is 




b) Identify FOUR (4) common symptoms of menopause and why they occur.  Include in 







a) Provide THREE (3) examples of hormonal agents, acting via different mechanisms of 
action, used in the treatment of breast cancer.  Include in your answer a brief description 




b) Describe why ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) has 
replaced MOPP (mechlorethamine, vincristine, procarbazine, prednisone) as the clear-
cut standard for initial treatment for Hodgkin’s Lymphoma (HL) even though many 







End of Section B 
 
 
THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM 
ANY EXAMINATION VENUE IN ANY CIRCUMSTANCE. THIS EXAMINATION IS PRINTED DOUBLE-SIDED. 
 
Semester 1, 2017 FINAL EXAMINATION 
 PHA411 – Therapeutics C 
Page 5 of 7 
 
Section C 
Case Study Questions 
Total Number of Marks for this section: 40 
 
This section should be answered in the Answer Booklet provided. 
 




Question 1 (24 marks) 
 
Mrs CS, a 61-year-old female, presents to her general practitioner with a persistent cough 
accompanied by haemoptysis, chest pain, shortness of breath and a 6-month history of weight 
loss and increasing fatigue.  She also complains of lower back pain and aching bones, irritability 
due to chronic headache and two days ago she had an episode when she “blacked out”.  Her 
husband witnessed the “black out” and insisted she see a doctor because it looked like she’d had 
a seizure. 
 
A chest X-ray and CT scan reveals a central mass causing obstruction of the middle lobe of her 
right lung, as well as lymphadenopathy.  Bronchoscopy washings and cytology are positive for 
small-cell lung cancer (SCLC).  Her LFT results show elevations in all parameters.  She denies 
exposure to environmental and occupational carcinogens including asbestos, but admits to a 3-
pack-per week history of cigarette smoking. 
 
 
a) Discuss the association between the aetiology and pathophysiology of SCLC and Mrs 
CS’s clinical signs and presentations.   Based on her symptoms, what is the likely stage 






b) What are the current recommendations for prevention and screening for early detection 
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e) Chemotherapy with etoposide and cisplatin is initiated.  Explain how these agents act to 





f) How should Mrs CS be monitored during therapy, taking into consideration the toxicities 
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Question 2 (16 marks) 
 
MM, a 67-year-old Caucasian man with a history of severe acne as a teenager is being 
evaluated in the dermatology clinic for a recent change in the intensity of a mole on his back.   
The characteristics of this mole are compared to a photograph taken 6 months earlier.  The  
results show that the mole is indeed darker and larger in diameter (currently 10mm), the border  
is ragged and irregular, and multiple shades of black and white colour are also noted.  About 3  
months ago, it began to itch. 
 
MM has blue eyes, blonde hair, a fair complexion and a moderate amount of freckling.  He was  
a concreter for most of his working life, and also worked on a prawn trawling vessel in his  
teens and early 20s.  He has a history of numerous blistering sunburns in his childhood and  
teenage years, and he currently still enjoys outdoor activities such as swimming, skiing and golf  
with his wife.  He admits that on numerous occasions he did not use sunscreen during his  
outdoor activities because it simply was not available when he was a young man, and at other  
times he forgot to take it with him.  MM does not have a family history of melanoma and he  
smokes two packs of cigarettes per week. 
 
 




















d) Outline a suitable treatment plan for MM if the biopsy of his resected sentinel lymph 




End of Section C 
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